DEF 14A: Organogenesis Holdings Seeks Stockholder Approval for Director Elections, Executive Pay, and Equity Incentive Plan Amendment

Organogenesis Holdings Inc. is holding its 2024 Annual Meeting of Stockholders on June 20, 2024, to vote on director elections, executive compensation, an equity incentive plan amendment, and ratification of the independent accounting firm.

Summary

• Organogenesis Holdings Inc. is convening its 2024 Annual Meeting of Stockholders virtually on June 20, 2024.
• Stockholders will vote on the re-election of eleven directors, including Alan A. Ades and Gary S. Gillheeney, Sr.
• An advisory vote will be held to approve the compensation paid to the named executive officers.
• Stockholders will also vote on an amendment to the 2018 Equity Incentive Plan to increase the number of shares of Class A common stock reserved for issuance by 15,900,000 shares.
• The meeting will also include a vote to ratify the appointment of RSM US LLP as the independent registered public accounting firm for fiscal year 2024.
• The board of directors recommends voting in favor of all proposals.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information and recommendations. The sentiment is neutral to positive, reflecting standard corporate governance procedures and a generally positive outlook for the company's ability to attract and retain talent.

Positives

• The proposed amendment to the 2018 Equity Incentive Plan aims to attract and retain highly qualified employees by offering equity incentives.
• The company is seeking stockholder input on executive compensation through an advisory vote.
• The board of directors is recommending experienced individuals for re-election as directors.
• The company is following good corporate governance practices by seeking ratification of the appointment of the independent registered public accounting firm.

Risks

• Failure to approve the amendment to the 2018 Equity Incentive Plan could hinder the company's ability to attract and retain key employees.
• The advisory vote on executive compensation could result in negative feedback from stockholders if they disapprove of the current compensation structure.
• If stockholders fail to ratify the appointment of RSM US LLP, the audit committee will reconsider whether to retain RSM US LLP, and may retain that firm or another without re-submitting the matter to our stockholders.

Future Outlook

The company intends to register the additional shares reserved for issuance under the 2018 Plan by filing a registration statement on Form S-8 following stockholder approval. This amendment is intended to provide a sufficient number of shares of common stock for anticipated awards to eligible persons through April 19, 2027.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy solicitations, director elections, executive compensation disclosures, and equity incentive plans. The peer group data is used to help identify a reasonable benchmark for base salaries, annual discretionary cash bonuses and long-term equity-based incentive compensation and then analyzed company and individual performance to determine whether it was appropriate to move away from this baseline.

Comparison to Industry Standards

• The document outlines standard practices for publicly traded companies, such as director elections, executive compensation, and equity incentive plans.
• The company benchmarks its executive compensation against a peer group of companies in the biotechnology, medical device, life sciences, and biopharmaceutical industries, including Alphatec Holdings, Inc., LeMaitre Vascular, Inc., and MiMedx Group, Inc.
• The company's compensation policies, including the prohibition of repricing stock options and stock appreciation rights without stockholder approval, align with industry best practices.

Related Party Transactions

• The buildings the company occupies in Canton, Massachusetts are owned by entities controlled by Alan Ades, Albert Erani, Dennis Erani and Glenn Nussdorf.
• The company made aggregate payments under the leases of $1,329,504, $1,295,696 and $2,612,709 in 2023.
• Gary Gillheeney, Jr., Vice President, Customer Experience, and James Gillheeney, regional sales manager, are children of Gary S. Gillheeney, Sr., President and Chief Executive Officer.

Stakeholder Impact

• Approval of the equity incentive plan amendment could positively impact employees by providing them with equity-based compensation.
• The outcome of the advisory vote on executive compensation could influence future compensation decisions and impact executive morale.
• The election of directors will determine the composition of the board and its ability to guide the company's strategy and performance.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on June 20, 2024, to discuss and vote on the proposals.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Equity Incentive Plan, RSM US LLP, Audit Firm, Voting, Organogenesis